Mark J. Biagi
Clinical Assistant Professor, College of Pharmacy - Pharmacy Practice
Clinical Instructor, College of Pharmacy - Pharmacy Practice
Email:
Related Sites:
About
Teaching and Supervision
Clinical Applications (PHAR 520), 8/25/2025 – 12/5/2025
Clinical Applications (PHAR 520), 8/25/2025 – 12/5/2025
PMPR 385: Media’s Influence of Critical Care and Emergency Medicine. Bioterrorism Outbreak, 9/1/2024 – 9/30/2024
PMPR 338: Management of the HIV Patient. Topic: Management of Antiretroviral Resistance, 9/1/2024 – Present
PHAR 413: Introductory Pharmacy Practice (IPPE): Hospital. Topic: Medical Emergency and Crash Cart Overview, 8/15/2024 – Present
PHAR 520: Clinical Pharmaceutics, Pharmacokinetics, & Pharmacogenomics. Topic: Aminoglycoside PK/PD & Toxicodynamics, 8/15/2024 – Present
PHAR 520: Clinical Pharmaceutics, Pharmacokinetics, & Pharmacogenomics. Topic: Vancomycin PK/PD & Toxicodynamics, 8/15/2024 – Present
PHAR 520: Clinical Pharmaceutics, Pharmacokinetics, & Pharmacogenomics. Topic: PK/PD Alterations in Renal Disease, 8/1/2024 – Present
PHAR 506: Infectious Diseases. Topic Antimicrobial PK/PD II, 1/1/2024 – 5/31/2024
Selected Grants
Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients, Merck Sharp & Dohme Corp., 1/6/2022 - 1/6/2025, No Obligated Amount Set; Anticipated Amount: $137232.72
ACTIV-4c: COVID-19 Post-Hospital Thrombosis Prevention Study, National Institutes of Health., 4/1/2021 - Present, No Obligated Amount Set; No Anticipated Amount Set
Real World Multicenter Observational Study of Imipenem-Cilastatin-Relebactam for Gram-Negative Infections, Merck & Co., Inc.., 4/1/2021 - Present, No Obligated Amount Set; No Anticipated Amount Set
Multicenter Observational Study of Dalbavancin for Invasive Bloodstream Infections, Allergan Inc.., 4/1/2021 - Present, No Obligated Amount Set; No Anticipated Amount Set
ACTIV-4 ACUTE: COVID-19 Acute Inpatient Antithrombotic Study, National Institutes of Health., 10/1/2020 - Present, No Obligated Amount Set; No Anticipated Amount Set
Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to those on Vancomycin and Ceftolozane-Tazobactam, Merck & Co.., 8/1/2020 - Present, No Obligated Amount Set; No Anticipated Amount Set
Real-world experience with eravacycline at academic hospital systems, Tetraphase Pharmaceuticals., 2/1/2020 - Present, No Obligated Amount Set; No Anticipated Amount Set
Aztreonam + ceftazidime/avibactam against Stenotrophomonas maltophilia, Cystic Fibrosis Foundation., 6/1/2019 - 11/30/2020, Obligated Amount: $54000; Anticipated Amount: $54000
Evaluation of omadacycline activity against minocycline-susceptible and –resistant Acinetobacter baumannii, Paratek Pharmaceuticals., 5/2019 - 5/2019, No Obligated Amount Set; No Anticipated Amount Set
Selected Publications
Al Musawa, Mohammed, Kunz Coyne, Ashlan J, Alosaimy, Sara, Lucas, Kristen, Schrack, Melanie Rae, Andrade, Justin, Herbin, Shelbye R, Biagi, Mark, Pierce, Michael, Molina, Kyle C, DeKerlegand, Alaina, Perkins, Nicholson B, Cosimi, Reese, Kang-Birken, Lena, King, Madeline A, Pullinger, Benjamin M, Rojas, Leonor M, Bouchard, Jeannette, Hobbs, Athena LV, Agee, Jazmin, Caniff, Kaylee E, Van Helden, Sean R, Veve, Michael P, Rybak, Michael J. (2025). Correction: Clinical Outcomes of Eravacycline in Patients Treated for Stenotrophomonas maltophilia Infections. Infectious Diseases and Therapy, 14, (11), 2637-2638. doi:10.1007/s40121-025-01242-y.
Coyne, Ashlan J Kunz, Alosaimy, Sara, Lucas, Kristen, Morrisette, Taylor, Molina, Kyle C, DeKerlegand, Alaina, Schrack, Melanie Rae, Kang-Birken, S Lena, Hobbs, Athena LV, Agee, Jazmin, Perkins, Nicholson B, Biagi, Mark, Pierce, Michael, Truong, James, Andrade, Justin, Bouchard, Jeannette, Gore, Tristan, King, Madeline A, Pullinger, Benjamin M, Claeys, Kimberly C, Herbin, Shelbye, Cosimi, Reese, Tart, Serina, Veve, Michael P, Jones, Bruce M, Rojas, Leonor M, Feehan, Amy K, Zhao, Jing J, Witucki, Paige, Rybak, Michael J. (2025). Eravacycline use in immunocompromised patients: multicenter evaluation of timely versus late initiation on clinical outcomes. Microbiology Spectrum, 13, (10), e00565-e00525. doi:10.1128/spectrum.00565-25.
Al Musawa, Mohammed, Kunz Coyne, Ashlan J, Alosaimy, Sara, Lucas, Kristen, Schrack, Melanie Rae, Andrade, Justin, Herbin, Shelbye R, Biagi, Mark, Pierce, Michael, Molina, Kyle C, DeKerlegand, Alaina, Perkins, Nicholson B, Cosimi, Reese, Kang-Birken, Lena, King, Madeline A, Pullinger, Benjamin M, Rojas, Leonor M, Bouchard, Jeannette, Hobbs, Athena LV, Agee, Jazmin, Caniff, Kaylee E, Van Helden, Sean R, Veve, Michael P, Rybak, Michael J. (2025). Clinical Outcomes of Eravacycline in Patients Treated for Stenotrophomonas maltophilia Infections. Infectious Diseases and Therapy, 14, (7), 1499-1511. doi:10.1007/s40121-025-01170-x.
Caniff, Kaylee E, Rebold, Nicholas, Xhemali, Xhilda, Tran, Nikki, Eubank, Taryn A, Garey, Kevin W, Guo, Yi, Chang, Mei, Barber, Katie E, Krekel, Tamara, Biagi, Mark, Kufel, Wesley D, Carr, Amy, Hayes, Jillian, Carlson, Travis J, Frens, Jeremy, Venugopalan, Veena, Lucas, Kristen, Coyne, Ashlan J Kunz, Sanders, James, Chandler, Elisabeth, Li, Rosanna, Antosz, Kayla, Justo, Julie Ann, Benefield, Russell, Moore, W Justin, Ross, Jennifer, Adams, Jenna, Albarillo, Fritzie, Stefanos, Sylvia, Hobbs, Athena LV, Mercuro, Nicholas, Raux, Brian, Zeitler, Kristen, Rybak, Michael J. (2025). Real-World Applications of Imipenem-Cilastatin-Relebactam: Insights From a Multicenter Observational Cohort Study. Open Forum Infectious Diseases, 12, (4), ofaf112. doi:10.1093/ofid/ofaf112.
Caniff, Kaylee E, Xhemali, Xhilda, Tran, Nikki, Eubank, Taryn A, Garey, Kevin W, Guo, Yi, Chang, Mei H, Barber, Katie, Biagi, Mark, Carlson, Travis J, Frens, Jeremy J, Krekel, Tamara, Veena, Venugopalan, Kufel, Wesley D, Carr, Amy L, Hayes, Jillian, Sanders, James, Chandler, Elisabeth, Li, Rosanna, Justo, Julie Ann, Antosz, Kayla, Benefield, Russell J, Moore, William Justin, Ross, Jennifer K, Hobbs, Athena LV, Mercuro, Nicholas, Raux, Brian, Zeitler, Kristen, Rybak, Michael J. (2025). P-1500. Evaluation of Imipenem-cilastatin-relebactam for the Treatment of Infections Caused by Pseudomonas aeruginosa. Open Forum Infectious Diseases, 12, (Supplement_1), ofae631.1669. doi:10.1093/ofid/ofae631.1669.
Biagi, Mark, Pierce, Michael, Harney, Wendy, Pereira-Rodrigues, Otavio, Tsaras, Geoffrey. (2025). Graded isavuconazonium sulfate challenge in a patient with hypersensitivity to fluconazole. IDCases, 42, e02355. doi:10.1016/j.idcr.2025.e02355.
Bulman, Zackery P, Cao, Lishan, Curry, Brooke N, Biagi, Mark, Vivo, Amanda, Suda, Katie J, Evans, Charlesnika T. (2024). Ceftazidime/avibactam alone or in combination with an aminoglycoside for treatment of carbapenem-resistant Enterobacterales infections: A retrospective cohort study. International Journal of Antimicrobial Agents, 64, (5), 107321. doi:10.1016/j.ijantimicag.2024.107321.
Hemenway, Alice N, Biagi, Mark, Murrey, Timothy F, Sun, Jiehuan, Osei-Badu, Erica, Salazar-McKinney, Adriana, Sanabria, Ricardo, Al Zoubi, Moamen. (2024). Association of Race or Ethnicity With Extended-Spectrum Beta-Lactamase Production in Escherichia Coli: A Case Control Study. Open Forum Infectious Diseases, 11, (10), ofae516. doi:10.1093/ofid/ofae516.
Rebold, Nicholas, Alosaimy, Sara, Pearson, Jeffrey C, Dionne, Brandon, Taqi, Ahmad, Lagnf, Abdalhamid, Lucas, Kristen, Biagi, Mark, Lombardo, Nicholas, Eudy, Joshua, Anderson, Daniel T, Mahoney, Monica V, Kufel, Wesley D, D’Antonio, Joseph A, Jones, Bruce M, Frens, Jeremy J, Baumeister, Tyler, Geriak, Matthew, Sakoulas, George, Farmakiotis, Dimitrios, Delaportas, Dino, Larew, Jeremy, Veve, Michael P, Rybak, Michael J. (2024). Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study. Infectious Diseases and Therapy, 13, (3), 565-579. doi:10.1007/s40121-024-00933-2.
Professional Leadership
Clostridioides difficile committee, SwedishAmerican Hospital, 2/1/2020 - Present
Education
Degrees:
Doctor of Pharmacy, University of Illinois at Chicago, United States, 2016
Bachelor of Science, University of Illinois at Chicago, United States, 2012
Postgraduate Training:
PGY-1 Pharmacy Practice Resident, Franciscan Health, United States, 2017